The FDA has approved updated labeling for Sublocade (buprenorphine extended-release) injection to include a rapid induction protocol and alternative injection sites.

Self-pay patients with obesity now have additional vial options as well, including at 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. Lilly is also slashing the price for a month's supply of the two lowest ...

Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from ...

Eli Lilly released higher doses of its weight loss drug ... vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the blockbuster injection ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

and the cheaper price point could sway more customers away from compounded copies of the drug, according to analysts. Eli Lilly began offering vials of the two lowest doses of Zepbound ...

Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...